|
Found 4 result(s) FROM 1963 pages containing the term 'SOCS3 expression'.
Thursday Nov 16, 2006
Can-Fite Presents Results Showing a Correlation Between High Expression of the Receptor Target for Its Drug CF101 and Rheumatoid Arthritis Patients' Response to the Drug
Can-Fite BioPharma Ltd, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small molecule A(3) adenosine receptor (A[3]AR) agonists with potent activities in inflammation and cancer, announced that it presented results showing a correlation between high expression of the receptor target for its investigational A(3)AR agonist CF101 and the response of rheumatoid arthritis (RA) patients to treatment with the drug, at the 70th Annual Meeting of the American College of Rheumatology and the 41st Annual Meeting of the Association of Rheumatology Health Professionals in Washington, DC.
Wednesday Jan 18, 2006
Combination of cDNA Expression Library and Whatman Protein Microarray Technology Led to Identification of Potential Autoantigens in the Pathogenesis of Alopecia Areata
Whatman, plc (Middlesex, UK), and Protagen, AG (Dortmund, Germany), have issued a joint statement announcing that the combination of two promising technologies...
Tuesday Dec 20, 2005
Research Outlines Novel Role of IL-1, IGF-1 in Cartilage Damage of Arthritis
A new study by Dutch investigators suggests that interleukin-1 (IL-1)-induced suppression of cytokine signaling (SOCS) 3 renders chondrocytes insensitive to insulin-like growth factor-1 (IGF-1), a novel mechanism that appears to contribute to cartilage damage in arthritis...Van der Loo FAJ, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass.
Monday Dec 13, 2004
Synovial Tissue Interleukin-18 Expression Correlates With Inflammatory Arthritis Disease Activity
New study underscores the important proinflammatory role of IL-18 in the pathophysiology of inflammatory arthritis, and suggests that treatment that inhibits or neutralizes endogenous IL-18 may become an effective tool in controlling synovial tissue inflammation&Rooney T, et al. Ann Rheum Dis. 2004;63:1393-1398.
|
